Houston, TX, October 08, 2015 --(PR.com
)-- Searching the globe for the next early-stage healthcare technology poised to disrupt the market, Cleveland Clinic Innovations named Noninvasix Inc., developers of a first-in-class fetal wellness monitor, as a finalist in its 2015 New Ventures Healthcare Challenge.
On Monday, October 26, the remaining four finalists will present their groundbreaking technologies before a panel of investors and healthcare technology experts and a general audience of clinicians and industry professionals at the 2015 Medical Innovation Summit in Cleveland, Ohio.
Unlike ineffective fetal heart rate monitors, Noninvasix’s optoacoustic fetal probe uses direct, real-time monitoring of cerebral venous oxygenation in the fetus’ superior sagittal sinus to determine the baby’s welfare. By rapidly and accurately detecting the amount of oxygen a baby is receiving during active labor, the company aims to reduce the incidents of unnecessary cesarean sections and the risk of severe neonatal morbidity including cerebral palsy and malpractice lawsuits.
“Cleveland Clinic Innovations has a great reputation for identifying breakthrough technologies, and we’re humbled to be recognized among the most innovative,” said Noninvasix CEO Graham Randall, Ph.D. “We’d love nothing more than to be the last company standing, but the opportunity to present before such an influential audience of industry leaders is invaluable.”
In addition to Noninvasix, finalists in the New Ventures Healthcare Challenge include ExplORer, Twiage and Varsa Health.
The winner of the grueling three-round competition, which began in June, will receive a free consultation from commercialization experts at Cleveland Clinic Innovations and its Innovation Advisory Board. The winning company will be featured in various Cleveland Clinic Innovations promotions, and will have the opportunity to showcase its product to a select group of Cleveland Clinic caregivers.
For thirteen years, Cleveland Clinic Innovations, the commercialization arm of Cleveland Clinic, has hosted the four-day Medical Innovation Summit, which brings together more than 1,700 healthcare investors, clinicians and technologists. Final presentations of the New Ventures Healthcare Challenge will kick off the Summit.
About Noninvasix, Inc.
Using patented optoacoustic technology, Houston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and non-invasive monitoring of fetal welfare during labor and delivery. Noninvasix’s undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research and $2 million in seed funding. For more information, visit www.noninvasix.com.